Not Yet RecruitingPhase 4

Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease

400 participantsStarted 2026-04-01

Plain-language summary

This study aims to evaluate whether the combination of palmitoleic acid with infliximab can improve intestinal mucosal healing in patients with Crohn's disease compared with infliximab alone.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adult patients aged 18 to 75 years.
✓. Established diagnosis of Crohn's disease confirmed by radiologic, histologic, or endoscopic evidence.
✓. Active Crohn's disease at screening, defined as a Crohn's Disease Activity Index (CDAI) score between 220 and 450 (inclusive).
✓. Adequate cardiac, renal, and hepatic function, as assessed by the investigator based on screening laboratory tests, physical examination, and medical history, without findings that would pose an undue risk for study participation.
✓. Willingness and ability to provide written informed consent.
✓. Agreement to undergo all scheduled study procedures, including up to 3 endoscopic evaluations.

Exclusion criteria

✕. Use of any biologic therapy (e.g., infliximab, adalimumab, ustekinumab, vedolizumab) within 8 weeks prior to screening.
✕. Use of supplements containing fish oil or other lipid supplements (e.g., macadamia oil, krill oil, flaxseed, primrose oil, sea buckthorn oil) within 8 weeks prior to screening.
✕. History of any intestinal resection or other Crohn's disease-related surgery.
✕. History of or active chronic or recurrent infectious disease.
✕. History of or current malignancy.
✕. Pregnancy, lactation, or intention to become pregnant during the study period.
✕. Known hypersensitivity to infliximab or palmitoleic acid preparations.

What they're measuring

Complete mucosal healing

Timeframe: From enrollment to the end of treatment at 26 weeks

Trial details

NCT IDNCT07417696

SponsorChinese Medical Association

Sponsor typeNETWORK

Study typeINTERVENTIONAL

Primary completion2029-03-31

View on ClinicalTrials.gov More Crohn's Disease trials